Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)”

54 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 54 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05253118
What this trial is testing

Relapsed or Refractory Primary Diffuse Large B-cell Lymphoma (DLBCL) of the Central Nervous System (CNS)

Who this might be right for
DLBCL
Seoul National University Hospital 28
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06062641
What this trial is testing

Selinexor Combined With R-GDP Regimen for TP53-altered R/R DLBCL

Who this might be right for
Relapsed or Refractory B-cell Lymphoma
Ruijin Hospital 50
Large-scale testing (Phase 3)Ended earlyNCT04236141
What this trial is testing

Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).

Who this might be right for
Diffuse, Large B-Cell, Lymphoma
Hoffmann-La Roche 42
Testing effectiveness (Phase 2)Study completedNCT02142049
What this trial is testing

Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Who this might be right for
Diffuse Large B Cell Lymphoma RelapsedDiffuse Large B Cell Lymphoma Refractory
Pharmacyclics LLC. 35
Testing effectiveness (Phase 2)Looking for participantsNCT07489989
What this trial is testing

Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination.

Who this might be right for
Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
Daihong Liu 30
Testing effectiveness (Phase 2)UnknownNCT03373019
What this trial is testing

Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Who this might be right for
ChidamideLymphoma, B-CellLymphoma, Large B-Cell, Diffuse+13 more
Fudan University 63
Not applicableStudy completedNCT04150328
What this trial is testing

Lenalidomide Monotherapy in R/R DLBCL

Who this might be right for
Diffuse Large B Cell Lymphoma
MorphoSys AG 490
Early research (Phase 1)Study completedNCT05665530
What this trial is testing

PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies

Who this might be right for
Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Mantle Cell Lymphoma (MCL)+9 more
Prelude Therapeutics 86
Testing effectiveness (Phase 2)Looking for participantsNCT07255963
What this trial is testing

Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL

Who this might be right for
DLBCL - Diffuse Large B Cell Lymphoma
The First Affiliated Hospital of Soochow University 29
Not applicableUnknownNCT05883709
What this trial is testing

A Real-world Study of Tafasitamab in Combination With Lenalidomide in Patients withR/R DLBCL

Who this might be right for
Diffuse Large B-cell Lymphoma
Zhao Weili 15
Early research (Phase 1)Active Not RecruitingNCT01959698
What this trial is testing

Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma

Who this might be right for
CD20 PositiveRecurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma+4 more
Roswell Park Cancer Institute 29
Early research (Phase 1)Ended earlyNCT03876028
What this trial is testing

Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients

Who this might be right for
Diffuse Large B-cell Lymphoma
Novartis Pharmaceuticals 10
Testing effectiveness (Phase 2)WithdrawnNCT05966233
What this trial is testing

R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Who this might be right for
Diffuse Large B Cell Lymphoma RefractoryDiffuse Large B-cell Lymphoma Recurrent
Fondazione Italiana Linfomi - ETS
Early research (Phase 1)Active Not RecruitingNCT05753501
What this trial is testing

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

Who this might be right for
Hematologic Cancer
AbbVie 135
Large-scale testing (Phase 3)Study completedNCT02763319
What this trial is testing

A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Who this might be right for
Diffuse Large B-cell Lymphoma
Incyte Corporation 453
Not applicableAvailableNCT05619367
What this trial is testing

A Compassionate Use (CU) Program of Odronextamab

Who this might be right for
Relapsed or Refractory (R/R) Follicular Lymphoma (FL)Diffuse Large B-Cell Lymphoma (DLBCL)B-Cell Non-Hodgkin Lymphoma (NHL)+1 more
Regeneron Pharmaceuticals
Early research (Phase 1)Study completedNCT04049825
What this trial is testing

Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL

Who this might be right for
Relapsed or Refractory Diffuse Large B-cell Lymphoma
Otsuka Pharmaceutical Co., Ltd. 36
Large-scale testing (Phase 3)Ended earlyNCT02951156
What this trial is testing

Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

Who this might be right for
Diffuse Large B-Cell Lymphoma
Pfizer 29
Testing effectiveness (Phase 2)UnknownNCT05498636
What this trial is testing

SPEL as Introductive Treatment Following Immune-chemotherapy as Consolidated Therapy for R/R DLBCL With p53 and/or c-Myc Expression

Who this might be right for
DLBCL
The Affiliated Hospital of Qingdao University 67
Testing effectiveness (Phase 2)Study completedNCT01562977
What this trial is testing

Study to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCL

Who this might be right for
Aggressive LymphomaDiffuse Large B-cell LymphomaMantle Cell Lymphoma
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea 82
Load More Results